| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T44 |
0-139 |
Sentence |
denotes |
Currently, there are no data describing the benefits or risks of stopping immunomodulators/immunosuppressants during the COVID-19 outbreak. |
| T45 |
140-285 |
Sentence |
denotes |
However, each medication's mechanism of action, administration method/frequency, and pharmacokinetics/pharmacodynamics are important to consider. |
| T46 |
286-458 |
Sentence |
denotes |
Nonbiologic medications, including small molecule inhibitors and immunosuppressants, are typically easier to stop and restart within days to weeks due to shorter half-life. |
| T47 |
459-617 |
Sentence |
denotes |
Meanwhile, biologics generally have a longer half-life and include a risk of antidrug antibody formation with treatment cessation and subsequent continuation. |
| T48 |
618-753 |
Sentence |
denotes |
However, biologics also tend to be more targeted and less involved in the previously mentioned components of the viral immune response. |
| T49 |
754-812 |
Sentence |
denotes |
General medication considerations are included in Table I. |
| T50 |
813-928 |
Sentence |
denotes |
Although patient dependent, clinicians may consider weaning patients with stable disease off of immunosuppressants. |
